Table 2 Anticancer activity of the synthesized nanoformulae against colorectal (Caco-2) carcinoma.
Trial number | Sericin/propolis ratio | Stirring time (min) | IC50 Concentration (µg/ml) | Physical characteristics | ||
|---|---|---|---|---|---|---|
Zeta Potential (mV) | Size (nm) | PDI | ||||
1 | 1/1 | 15.0 | 94.40 ± 5.9 | 25.5 | 7540.0 | 0.27 |
2 | 1/1 | 30.0 | 53.14 ± 1.3 | 27.5 | 629.6 | 0.28 |
3 | 1/1 | 45.0 | 51.08 ± 0.9 | 35.6 | 166.1 | 0.65 |
4 | 1/1 | 60.0 | 32.09 ± 1.1 | 39.3 | 116.0 | 1.00 |
5 | 2/3 | 15.0 | 99.50 ± 6.7 | 28.6 | 1438.0 | 0.45 |
6 | 2/3 | 30.0 | 98.80 ± 3.7 | 33.3 | 642.3 | 0.47 |
7 | 2/3 | 45.0 | 87.80 ± 2.4 | 33.4 | 389.6 | 0.75 |
8 | 2/3 | 60.0 | 80.40 ± 10.7 | 40.4 | 143.2 | 0.97 |
9 | 1/2 | 15.0 | 284.24 ± 11.4 | 22.7 | 394.4 | 0.39 |
10 | 1/2 | 30.0 | 198.50 ± 12.3 | 23.0 | 362.8 | 0.41 |
11 | 1/2 | 45.0 | 184.04 ± 6.7 | 25.7 | 319.1 | 0.56 |
12 | 1/2 | 60.0 | 105.19 ± 0.8 | 27.2 | 270.3 | 0.46 |
13 | 3/2 | 15.0 | 47.38 ± 0.8 | 20.5 | 617.3 | 0.27 |
14 | 3/2 | 30.0 | 39.06 ± 1.9 | 23.0 | 375.0 | 0.31 |
15 | 3/2 | 45.0 | 35.01 ± 0.6 | 23.6 | 362.9 | 0.33 |
16 | 3/2 | 60.0 | 29.80 ± 1.7 | 24.8 | 269.9 | 0.36 |
17 | 2/1 | 15.0 | 68.20 ± 1.6 | 24.4 | 269.3 | 0.22 |
18 | 2/1 | 30.0 | 49.16 ± 2.4 | 28.2 | 268.0 | 0.24 |
19 | 2/1 | 45.0 | 47.20 ± 1.7 | 29.7 | 234.0 | 0.26 |
20 | 2/1 | 60.0 | 23.68 ± 2.6 | 32.7 | 222.6 | 0.30 |
